The European Commission, US National Institutes of Health and Genome Canada are today announcing a global collaborative research programme designed to lead to better understanding of human diseases. Although many genes have been linked to major diseases or conditions such as cancer, heart disease, neurological disorders, diabetes and obesity, research is still needed into why these genes are important and what their role is in the disease. As mice and humans share 99% of their genetic make-up, this international collaborative programme will study the activity of genes in mice, using a process that “knocks out” specific genes. This programme will help researchers unravel the genetic networks underlying disease. The project will cost a total of €56.6m, with the EU’s Research Framework Programme contributing €13m. The information on mutations in the mouse genome generated by the programme will be rapidly accessible to the worldwide scientific community, constituting a significant resource to help translate basic research into improvements in human health.
European Science and Research Commissioner Janez Potocnik welcomed the joint programme, saying “International scientific collaboration is in the interests of us all; pooling knowledge will increase our chance to make discoveries that can benefit human health. There is so much we still don’t know about the effect of genes on the development of our major diseases. Research like this gives hope to many of those suffering serious illnesses and their families.”
Our genetic material is composed of about 28 000 different genes. However, just identifying a gene does not tell much about its potential function in health and disease. To investigate this it is necessary to mutate the gene in a model organism that is closely related to humans. Genetically, the mouse is the model organism of choice for human disease research, as about 99% of human genes are found in the mouse genome and vice versa. In addition, a powerful mutagenesis technology has been developed, that currently can only be applied in the mouse to inactivate a specific gene in a time- and space-dependent manner. This approach allows researchers to unravel very precisely the genetic networks underlying disease.
Mutations in all the genes of a mammalian genome
The European Commission, US National Institutes of Health (NIH) and Genome Canada will finance the largest collaborative research effort (56.6 m€) worldwide after the Human Genome Project to produce mutations in all the mouse genes, using gene trapping and gene targeting approaches. This project will enable mouse mutants to be generated in any laboratory in a standardised and cost-effective manner, thereby making them available to a much wider biomedical research community than has been possible previously. This mutant resource will be of crucial importance for health research since it will allow scientists to dissect gene functions within a living organism (in vivo) more accurately and to mimic human disease conditions more closely. In doing so, it will also speed up significantly drug developments for the treatment of human diseases.
World-wide collaborative research effort in mouse mutagenesis
This world-wide mouse mutagenesis collaborative effort networks three major initiatives: The EUCOMM project financed by the European Commission with 13m€, the NorCOMM project which received 4.4 m€ from the Canadian government and the Knockout Mouse Project (KOMP) project financed by the US-NIH with 39.2 m€. A steering committee composed of the scientists leading these three research projects and representatives from the funding agencies will coordinate this collaborative effort to ensure complementarity and to avoid overlaps. These leading scientists and funding agencies have agreed to make freely accessible to the scientific community the mutant resources generated in their respective projects, thereby maximising the benefit of each of these projects. Other funding agencies and scientific projects involved in similar mouse mutagenesis programmes in other countries are also encouraged to join in this present effort provided they will agree to the same principle.
EU invests €135 million in mouse functional genomics
The European Union is a major sponsor of mouse functional genomics research. Since 2002, fifteen ongoing European collaborative projects have received a total of €135 million from the EU’s Fifth and Sixth Framework Programmes. They are using the mouse as a model for elucidating gene functions in health and disease. Some of these projects are developing new tools, technologies, and resources that are essential for the success of mouse functional genomics. Other projects are using mouse models to investigate the functions of key genes involved in important biological processes such as hearing, muscle formation, kidney function angiogenesis embryonic stem cell differentiation and the immune system
For information on research financed by the European Union: www.ec.europa.eu/research .
EUCOMM project coordinators
Prof. Dr. Wolfgang Wurst
Institute of Developmental Genetics, GSF - National Research Center for Environment and Health, Munich/Neuherberg and Technical University Munich
Tel: +49.89.31 87-41 10, E-mail: email@example.com
Prof. Allan Bradley, PhD
The Wellcome Trust Sanger Institute
Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
Phone: +44.(0)1223.494884, E-mail: firstname.lastname@example.org
EU Scientific officer
Jacques Remacle, F4 Unit, Research DG
Tel: +32.2.296 30 45, E-mail: email@example.com
Michael H. Wappelhorst, Press and information officer, Research DG
Tel.: +32.2.298 75 75, Fax: +32.2.295 82 20, E-mail: Michael.Wappelhorst@ ec.europa.eu
Spokesperson for Science and Research
Antonia Mochan, Press and Communication DG, European Commission
Tel.: +32.2.2996 9921, E-mail Antonia.Mochan@ec.europa.eu